Intas Pharmaceuticals, Limited. et al. vs. Atossa Therapeutics, Inc.
Explore the PTAB proceeding PGR2023-00043 filed by Intas Pharmaceuticals, Limited. et al. on 2023-08-18. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
PGR2023-00043
Filing Date
2023-08-18
Accorded Filing Date
2023-08-18
Institution Decision Date
2024-01-31
Last Modified Date
2025-04-07
Proceeding Type
PGR
Termination Date
2025-01-29
Trial Status
Final Written Decision
Parties & Counsel
Petitioner
Intas Pharmaceuticals, Limited. et al.
Represented By
Menchaca, Alejandroet alPatent Owner / Respondent
Atossa Therapeutics, Inc.
Represented By
Harwood, Melissaet alPatent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Decisions Rendered
2 Total
Proceeding Status
Final Written Decision
Administrative Patent Judges (APJ Panel)
Board Decisions & Rulings (2)
Address and Attorney/Agent Information
Power of Attorney & Correspondence
Attorney / Agent Information
| Reg # | Name | Phone |
|---|---|---|
| 29476 | John Pratt | +1 404-815-6500 |
| 31741 | Theodore Brown Iii | +1 650-326-2400 |
| 31814 | Charles Calkins | +1 336-607-7300 |
| 31836 | Paul Haughey | +1 415-273-4787 |
| 33160 | Steven Borgman | +1 281-809-4100 |
| 33452 | Dean Russell | +1 404-815-6500 |
| 35687 | Susan Spaeth | +1 650-324-6335 |
| 36974 | Roger Wylie | +1 206-516-3092 |
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 15 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 11,572,334 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,680,036 B1 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 12,071,391 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 12,281,056 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 12,275,684 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2025028271 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 12,479,790 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2026002830 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2026020082 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2017625568 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2017625567 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2018626247 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2018626938 | US Continuation / Sibling | View Official Patent → |
| 🌐 PCT International (WIPO) | WO 2019051416 A1 | PCT World Application | View Official Patent → |
| 🇺🇸 United States | US 2020166419 | US Continuation / Sibling | View Official Patent → |
Intas Pharmaceuticals, Ltd. et al. v. Atossa Therapeutics, Inc.